DRTS ALPHA TAU MEDICAL LTD.

Alpha Tau to Present at the J.P. Morgan 2026 Healthcare Conference

Alpha Tau to Present at the J.P. Morgan 2026 Healthcare Conference

- The overview presentation will review some of the Company’s recent achievements as well as the outlook for upcoming data milestones -

JERUSALEM, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, today announced that CEO Uzi Sofer and CFO Raphi Levy will present a corporate overview and update at the J.P. Morgan 2026 Healthcare Conference on Thursday, January 15, 2026 at 11:15am PT / 2:15pm ET, in San Francisco, CA, and will host institutional investor meetings at the event.

Event:J.P. Morgan 2026 Healthcare Conference
Format:Presentation and 1-on-1 Meetings
Date:January 15, 2026
Time:11:15AM PT – 11:55AM PT
Location:Westin St. Francis, San Francisco, CA

Webcast: Link will be posted on the “Events & Presentations” page in the Investor Relations section on the Company’s website at

Please reach out to your J.P. Morgan representative to schedule 1-on-1 meetings with Mr. Sofer and Mr. Levy.

About Alpha Tau Medical Ltd.

Founded in 2016, Alpha Tau is an Israeli oncology therapeutics company that focuses on research, development, and potential commercialization of the Alpha DaRT for the treatment of solid tumors. The technology was initially developed by Prof. Itzhak Kelson and Prof. Yona Keisari from Tel Aviv University.

About Alpha DaRT ®

Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy) is designed to enable highly potent and conformal alpha-irradiation of solid tumors by intratumoral delivery of radium-224 impregnated sources. When the radium decays, its short-lived daughters are released from the sources and disperse while emitting high-energy alpha particles with the goal of destroying the tumor. Since the alpha-emitting atoms diffuse only a short distance, Alpha DaRT aims to mainly affect the tumor, and to spare the healthy tissue around it.

Investor Relations Contact: 



EN
18/12/2025

Underlying

DRTSALPHA TAU MEDICAL LTD.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ALPHA TAU MEDICAL LTD.

 PRESS RELEASE
Free
DRTS ALPHA TAU MEDIC...

Alpha Tau Announces First-Ever Oral Presentation of Alpha DaRT® Pancre...

Alpha Tau Announces First-Ever Oral Presentation of Alpha DaRT® Pancreatic Cancer Data at Digestive Disease Week (DDW) 2026 JERUSALEM, March 31, 2026 (GLOBE NEWSWIRE) -- . (Nasdaq: DRTS, DRTSW) (“Alpha Tau”), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT® today announced that an abstract presenting results of two clinical trials in Jerusalem in patients with pancreatic cancer has been accepted for an oral presentation at Digestive Disease Week (DDW) 2026, the world’s premier international gastroenterology conference. This marks the first time that clinical resu...

March 31, 2026 1 EN
 PRESS RELEASE
Free
DRTS ALPHA TAU MEDIC...

Alpha Tau to Present at Sidoti March Virtual Small Cap Conference

Alpha Tau to Present at Sidoti March Virtual Small Cap Conference JERUSALEM, March 16, 2026 (GLOBE NEWSWIRE) -- . (Nasdaq: DRTS, DRTSW) ("Alpha Tau"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT® today announced that CFO Raphi Levy will present at the Sidoti Virtual Small Cap Conference taking place on March 18-19, 2026. Event:Sidoti Virtual Small Cap ConferenceFormat:Company PresentationDate:March 18, 2026Time:10:00 – 10:30AM ETLocation:Virtual Mr. Levy will be available for 1x1 investor meetings at the conference. Please reach out to your Sidoti representat...

March 16, 2026 1 EN
 PRESS RELEASE
Free
DRTS ALPHA TAU MEDIC...

Alpha Tau Announces Full Year 2025 Financial Results and Provides Corp...

Alpha Tau Announces Full Year 2025 Financial Results and Provides Corporate Update - Tremendous activity in recent months, including receipt of Japanese marketing approval, the fifth parallel U.S. trial approval, data from pancreatic cancer trials presented at ASCO GI Symposium, and the first brain cancer treatment - - Multiple meaningful milestones targeted in the coming months, including completion of patient recruitment in the U.S. pivotal ReSTART skin cancer trial, in the U.S. pilot IMPACT pancreatic cancer trial, and in the U.S. recurrent glioblastoma multiforme feasibility trial - -...

March 9, 2026 1 EN
 PRESS RELEASE
Free
DRTS ALPHA TAU MEDIC...

Alpha Tau Medical Receives Japanese Marketing Approval for Alpha DaRT®...

Alpha Tau Medical Receives Japanese Marketing Approval for Alpha DaRT® in Unresectable Locally Advanced or Locally Recurrent Head and Neck Cancer - Approval establishes first clinical authorization outside Israel and initiates post-market surveillance program - - First-in-kind technology delivers intra-tumoral alpha-emitting radiotherapeutics, reflects strength of clinical data and strong collaboration with Japanese regulators and clinical societies - JERUSALEM, Feb. 24, 2026 (GLOBE NEWSWIRE) -- . (Nasdaq: DRTS, DRTSW) (“Alpha Tau”), the developer of the innovative alpha-radiation cance...

February 24, 2026 1 EN
 PRESS RELEASE
Free
DRTS ALPHA TAU MEDIC...

Alpha Tau Issues Letter to Shareholders: Five Concurrent Trials in the...

Alpha Tau Issues Letter to Shareholders: Five Concurrent Trials in the U.S. with Multiple Significant Value-Driving Milestones Ahead - Expecting very active 2026 from a clinical perspective, including significant patient accrual completions and subsequent data readouts from ReSTART pivotal skin cancer trial as well as trials in cancers of internal organs including the pancreas and brain - - Ramping U.S. manufacturing for commercial readiness - Jerusalem, Jan. 29, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: DRTS, DRTSW) ("Alpha Tau"), the developer of the innovative alpha-radiation cancer th...

January 29, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch